RxDoctor Payments DataLook up a doctor →

Elena Sidorenko, MD

Gastroenterology · la Crosse, WINPI 1831281674

Payments from drug & device makers

$13,490in general payments, 2019–2025

Across 672 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Gilead$696
  • Lilly USA, LLC$601
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$13,490100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,490 in reported general payments places this provider in the 85th percentile of 285 gastroenterology providers in Wisconsin.

See all gastroenterology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$173,835
Medicare patients
626
Services billed
1,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab22$514,268
XifaxanRifaximin13$28,482
LinzessLinaclotide32$24,842
MotegrityPrucalopride Succinate11$6,932
Esomeprazole Magnesium47$1,530
Famotidine84$1,467
Omeprazole102$1,384
Colestipol Hcl31$1,243
Pantoprazole Sodium46$807
Cholestyramine LightCholestyramine17$687
Rabeprazole Sodium14$464
Nortriptyline Hcl18$231
Dicyclomine Hcl20$230
Metronidazole19$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,180$514,26822 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$2,081$28,48213 claims
AbbVieLinzess$3,231$24,84232 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,034$6,93211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 285 gastroenterology providers in Wisconsin.

Other gastroenterology in la Crosse

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →